Work Package 3 Leader
Prof Bruno Frenguelli is Director of Sarissa Biomedical and Professor of Neuroscience at the University of Warwick. He is also Editor-in-Chief of the journal Neuropharmacology, has served on the UK REF2014 Neuroscience, Psychology and Psychiatry sub-panel and was Honorary Secretary of the British Neuroscience Association. He has been a long-standing collaborator of Prof Dale and an early adopter of purine biosensors.
Prof Frenguelli has 26 publications, specifically on purines, adenosine and ATP, which have collectively accumulated over 900 citations. He has an H index of 24 and nearly 4000 citations for his 45 publications and is a named inventor on a Sarrisa patent application. He has supervised 10 PhD students and 6 Postdoctoral researchers. His current funding is in excess of £700,000 and he has raised over £3M in grant funding in his career to date.
About Sarissa Biomedical:
Sarissa is an SME that began trading in 2004. Based on unique, proprietary, and highly adaptable patented methods, Sarissa makes the most complete range of microelectrode biosensors of any company in the world. Its commercially available product range consists of biosensors for 10 analytes (the most relevant to the current project being ATP, Adenosine, Inosine, Hypoxanthine, Lactate, Glutamate and D-serine). Sarissa is oriented towards R&D and is developing biosensors for 3 more analytes. Sarissa sells these microelectrode biosensors to research groups in many of the top universities around the world in the UK, USA, Europe and Japan and has also made significant sales into the pharmaceutical sector. In parallel with these activities, Sarissa has developed a range of biosensors (SarissaGold) and biosensor arrays (SMARTCap/SMARTChip) that utilize a surface-bound mediator to enable detection of these same 10 analytes with high specificity in unprocessed whole blood.
Sarissa now has extensive experience in using these devices with human patient samples. Sarissa has led two clinical trials to evaluate its devices: one on patients undergoing carotid artery surgery; and a second hospital study examining blood purines as a very early biomarker of stroke.